SUMMARY Thirty-two patients with duodenal ulceration took trimipramine 50 mg or placebo. Fifteen patients on each treatment completed the study. Endoscopy at four weeks showed ulcer healing in seven (46%) patients on trimipramine, compared with only two (15 %) on placebo (P<0-05). However, by eight weeks there were eight (53%) patients in both groups with healed ulcers. There were no significant differences between the two groups in ulcer symptoms. Drowsiness was reported by eight patients on trimipramine compared with only one on placebo. Trimipramine 50 mg appears to increase the rate of ulcer healing in the short term. Side-effects at the dose used may limit its long-term usefulness.
Trimipramine, a tricyclic antidepressant, has been shown by Myren and co-workersl-3 to be effective in healing duodenal ulcers. Though its mechanism of action is unclear, trimipramine appears to affect gastric secretion in a manner different from cimetidine or atropine.2 In a recent clinical trial trimipramine 25 mg compared favourably with cimetidine 400 mg,4 but was less effective than cimetidine 1000 mg. The dose of trimipramine in clinical studies has varied between 25 and 50 mg and sometimes large amounts of antacids have been given in addition.4 We therefore looked at the healing rates of duodenal ulcers in patients on trimipramine 50 mg or placebo, who were allowed only limited amounts of mild antacid. Thirty out of 32 patients completed the study. One patient on placebo witlhdrew because of ulcer symptoms, and one patient on trimipramine withdrew because of drowsiness which made him unsafe at work (roof tiling). Fifteen patients (four women and 11 men, mean age 42 years, including six smokers) received trimipramine, and an equal number received placebo (five women, 10 men, mean age 51 years, including six smokers). The two groups were well matched in their clinical characteristics.
Complete ulcer healing was noted in 46% of patients on trimipramine compared with 15°'0 on placebo after four weeks. The differences were significant (P < 0.05). However, 53°' , of patients in both groups had complete ulcer healing at eight weeks. (Table 1 Side-effects were commoner in the trimipramine group. Seven patients (excluding the one patient who withdrew) complained of drowsiness on trimipramine compared with only one patient on placebo. Patients on trimipramine also complained of dizziness (one), leg cramps (one), hot flushes (one), and depression (one). The placebo group complained of dizziness (two), headachle (one), palpitationis (one), and tiredness (one).
There were no changes in blood pressures, electrocardiograms, and laboratory tests in either group during the treatment period.
Discussion
In this study trimipramine increased the rate of dutodenal ulcer healing over a four week period, 
